RetaMaps

Altmed Clinic - Prevention Center USA - Waldorf

Altmed Clinic - Prevention Center USA - Waldorf · 11885 Holly Lane · Waldorf, MD 20601

5.0· 1 Google review

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

The official website for Altmed Clinic - Prevention Center USA - Waldorf in Waldorf, MD did not load (http 404), so this summary cannot be grounded in first-party page content. No medications, prices, or services are inferred from the directory dump.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 5.0
Google rating · 1 reviews

Counts computed by RetaMaps from public Google reviews; most recent review 2023-09-07. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★5.0 across 1 Google reviews. Of the 1 reviews we analyzed, 1 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).

5★
1
4★
0
3★
0
2★
0
1★
0

Most recent Google reviews

Matt B.★★★★★2023-09-07

Quality care & great service! Dr. Lee is the man

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Waldorf

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs